SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
Change Order Number 4Change Order • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations
IN WITNESS WHEREOF, the parties hereto have executed this Change Order by their duly authorised representatives on the date(s) written below.
AgreementConfidentiality Agreement • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations
This Agreement made this 15th day of November 2005 by and between Nisshin Pharma Inc., a Japanese corporation having its principal office at 25, Kanda-Nishikicho 1-chome, Chiyoda-ku, Tokyo, Japan (hereinafter referred to as “Nisshin”) and Amarin Pharmaceuticals Ireland Limited, an Irish Company (which is wholly owned by Amarin Corporation plc) having its principal office at 50 Pembroke Road, Dublin 2, (hereinafter referred to as “Amarin”) and Amarin Neuroscience limited, a Scottish company having its principle office at King Park House, Laurelhill Business Park, Polmaise Road, Stirling, UK,FK7 9JQ, in connection with the Agreement made on the 27th October 1999 between Nisshin Flour Milling Co., Ltd., a Japanese corporation, the parent company of Nisshin, and Laxdale Limited, a Scottish company now known as Amarin Neuroscience Limited due to the corporate take-over closed on the 8th October 2004 by Amarin Corporation plc, which was assigned on the 2nd July 2001 by Nisshin Flour Milling
DATED 17 MAY 2006 AND ASSIGNMENT AGREEMENT MATHESON ORMSBY PRENTICE Dublin 2 IrelandAssignment Agreement • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations • England
ContractClinical Trial Agreement • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations
Certain portions of this Exhibit have been omitted pursuant to a request for “Confidential Treatment” under Rule 24b-2 of the Securities and Exchange Commission. Such portions have been redacted and bracketed in the request and appear as [*] in the text of this Exhibit. The omitted confidential information has been filed with the Securities and Exchange Commission.
MASTER SERVICES AGREEMENTMaster Services Agreement • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations • England
BETWEEN ICON Clinical Research (UK) Limited doing business as ICON Development Solutions (hereinafter called “ICON”) of 2 Globeside, Globeside Business Park, Marlow, Bucks SL7 1HZ, UK
Change Order Number 3Change Order • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations
October 26, 2006Worldwide Exclusive License Agreement • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations
Dated 22 January, 2007 (1 ) Landlord: DAVID COLGAN, PHILIP MONAGHAN, FINIAN McDONNELL AND PATRICK RYAN (2 ) Tenant: AMARIN PHARMACEUTICALS IRELAND LIMITED (3 ) Guarantor: AMARIN CORPORATION PLC.Lease Agreement • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations
STOCK PURCHASE AGREEMENTStock Purchase Agreement • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
This Stock Purchase Agreement (the “Agreement”) is made as of the date set forth below between Amarin Corporation plc, a public limited company registered in England and Wales (the “Company”), and the Investors listed on Exhibit A.
PURCHASE AGREEMENTPurchase Agreement • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
